IN2015DN02377A - - Google Patents

Info

Publication number
IN2015DN02377A
IN2015DN02377A IN2377DEN2015A IN2015DN02377A IN 2015DN02377 A IN2015DN02377 A IN 2015DN02377A IN 2377DEN2015 A IN2377DEN2015 A IN 2377DEN2015A IN 2015DN02377 A IN2015DN02377 A IN 2015DN02377A
Authority
IN
India
Prior art keywords
luliconazole
derivative
pharmaceutical composition
composition containing
amide
Prior art date
Application number
Inventor
Takaaki; Masuda
Hirokazu; Kobayashi
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of IN2015DN02377A publication Critical patent/IN2015DN02377A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Means for controlling the formation amount of a formed amide form in relation to a pharmaceutical composition containing luliconazole is provided. Disclosed is a pharmaceutical composition containing 1) luliconazole and 2) one component or two or more components selected from carboxylic acid and derivative thereof , ketone, phosphoric acid and derivative thereof, local anesthetic , antihistamine , and POE based nonionic surfactant; wherein a content of an amide derivative of luliconazole is not more than 0.2% by mass with respect to a charged amount of luliconazole after storage at 60°C for 3 weeks or at 40°C for 6 months.
IN2377DEN2015 2012-09-14 2013-08-28 IN2015DN02377A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012203293 2012-09-14
PCT/JP2013/073731 WO2014042043A1 (en) 2012-09-14 2013-08-28 Pharmaceutical composition containing luliconazole

Publications (1)

Publication Number Publication Date
IN2015DN02377A true IN2015DN02377A (en) 2015-09-04

Family

ID=49226452

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2377DEN2015 IN2015DN02377A (en) 2012-09-14 2013-08-28

Country Status (7)

Country Link
US (1) US20150238606A1 (en)
EP (1) EP2895164A1 (en)
JP (2) JP5686874B2 (en)
CN (1) CN104619320A (en)
IN (1) IN2015DN02377A (en)
RU (1) RU2621615C2 (en)
WO (1) WO2014042043A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688405B2 (en) 2009-04-09 2015-03-25 株式会社ポーラファルマ Antifungal pharmaceutical composition
JP5688406B2 (en) 2009-04-09 2015-03-25 株式会社ポーラファルマ Antifungal pharmaceutical composition
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101806304B1 (en) 2010-06-11 2017-12-07 가부시키가이샤 폴라 파마 Antimycotic pharmaceutical composition
JP6265624B2 (en) * 2012-05-11 2018-01-24 ロート製薬株式会社 Luliconazole-containing external pharmaceutical composition
IN2015DN02376A (en) 2012-09-14 2015-09-04 Pola Pharma Inc
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
JP5460797B1 (en) * 2012-09-14 2014-04-02 株式会社ポーラファルマ Amide derivatives and their use as stability indicators
EP2895165B1 (en) 2012-09-14 2016-12-14 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
JP5589110B1 (en) 2013-03-08 2014-09-10 株式会社ポーラファルマ Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient
JP6503627B2 (en) * 2013-03-28 2019-04-24 大正製薬株式会社 Pharmaceutical liquid composition
JP5680161B1 (en) 2013-09-06 2015-03-04 株式会社ポーラファルマ Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient
JP6242655B2 (en) * 2013-10-29 2017-12-06 リンテック株式会社 Release method of functional substance, kit for releasing functional substance, and release composition
JP5587488B1 (en) 2013-12-12 2014-09-10 株式会社ポーラファルマ Evaluation method and index substance of preparation containing luliconazole
MX2018014485A (en) * 2016-05-25 2019-08-12 Glenmark Pharmaceuticals Ltd Luliconazole stable topicalcompositions.
CN107865825B (en) * 2016-09-28 2022-05-20 四川海思科制药有限公司 Luliconazole external spray pharmaceutical composition and preparation method thereof
CN108934161A (en) * 2017-03-29 2018-12-04 日本农药株式会社 For treating the medical composition of infectious disease
KR20200081432A (en) * 2017-10-30 2020-07-07 가껭세이야꾸가부시기가이샤 External preparations for the treatment of Cho, Seon-Seon
CN108143711A (en) * 2018-01-13 2018-06-12 天津双硕医药科技有限公司 A kind of medicinal external emulsifiable paste composition containing luliconazole
US10898470B1 (en) * 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
CN113774390B (en) * 2021-08-12 2023-08-04 上海新阳半导体材料股份有限公司 Cleaning liquid for chemical mechanical polishing and preparation method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102243A1 (en) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2025337B1 (en) 2006-03-08 2014-09-10 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
RU2423128C2 (en) 2006-03-08 2011-07-10 Нихон Нохияку Ко., Лтд. Pharmaceutical composition for external application
WO2009028495A1 (en) * 2007-08-27 2009-03-05 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
WO2009031642A1 (en) 2007-09-05 2009-03-12 Pola Pharma Inc. Pharmaceutical composition
EP2191828B1 (en) 2007-09-05 2016-08-10 Pola Pharma Inc. Antifungal pharmaceutical composition
WO2009031643A1 (en) * 2007-09-05 2009-03-12 Pola Pharma Inc. Antifungal composition
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
US8445717B2 (en) * 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
JP5654497B2 (en) * 2009-02-13 2015-01-14 トピカ ファーマシューティカルズ，インコーポレイテッド Antifungal preparation
JP5688406B2 (en) * 2009-04-09 2015-03-25 株式会社ポーラファルマ Antifungal pharmaceutical composition
JP5688405B2 (en) * 2009-04-09 2015-03-25 株式会社ポーラファルマ Antifungal pharmaceutical composition
WO2011024620A1 (en) * 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101806304B1 (en) * 2010-06-11 2017-12-07 가부시키가이샤 폴라 파마 Antimycotic pharmaceutical composition
KR20140008394A (en) * 2011-02-17 2014-01-21 시에이치디 바이오사이언스 인코포레이티드 Compositionis comprising peroxy a-ketocarboxylic acid and methods for producing and using the same

Also Published As

Publication number Publication date
JP2014111672A (en) 2014-06-19
JP2014074012A (en) 2014-04-24
JP5686874B2 (en) 2015-03-18
RU2621615C2 (en) 2017-06-06
CN104619320A (en) 2015-05-13
WO2014042043A1 (en) 2014-03-20
RU2015108930A (en) 2016-11-10
EP2895164A1 (en) 2015-07-22
JP6215102B2 (en) 2017-10-18
WO2014042043A9 (en) 2015-05-21
US20150238606A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
IN2015DN02377A (en)
WO2014167554A3 (en) Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
BR112014017749A8 (en) 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF
IN2014CN02527A (en)
IN2012DE00888A (en)
MX2016010056A (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof.
MY160249A (en) Fatty acid fumarate derivatives and their uses
MX355428B (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]- acetic acid.
MX2013005407A (en) 5-halogenopyrazolecarboxamides.
MY180903A (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
MX2015017373A (en) Personal care compositions and articles.
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
PH12015502154A1 (en) Composition for oral cavity
PH12015500334A1 (en) Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
MX2018015938A (en) Methods for inhibiting conversion of choline to trimethylamine (tma).
UA111357C2 (en) Epoxyeicosatrienoic acid analogs, composition based thereon, use in the treatment of diseases and method of reducing hypertension and nephrotoxicity
WO2014053401A3 (en) Method of improving plant health
MY168438A (en) Handy calco-magnesian suspension
BR112014002940A2 (en) use and agrochemical composition of carboxylic acid dibutylamides
SA518391664B1 (en) Composition for limiting the formation and/or agglomeration of gas hydrates
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
IN2014DN06122A (en)
PH12017500763A1 (en) Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
MX339727B (en) Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound.
MX2013004878A (en) N-hetarylmethyl pyrazolylcarboxamides.